Immuno-Oncology Market Size, Share, and Growth Forecast, 2026 – 2033

The global immuno-oncology market size is likely to be valued at US$66.2 billion in 2026 and is expected to reach US$296.8 billion by 2033, growing at a CAGR of 23.9% during the forecast period from 2026 to 2033, driven by the rising global cancer burden and the increasing adoption of immunotherapies as part of standard cancer treatment protocols.

According to the latest IARC estimates, approximately 20.6 million new cancer cases and 9.8 million cancer deaths were reported in 2024, underscoring the need for innovative and effective therapies. Meanwhile, the FDA continued to broaden immuno-oncology treatment options in 2026, including approvals for nivolumab in previously untreated Hodgkin lymphoma and T-cell-based therapies for hematologic malignancies, further supporting market expansion.

Driver - Technological Advances in Cell Therapy and Checkpoint Modulation

Technological advances are strengthening immuno-oncology by improving precision, durability, and scalability of therapies. Next-generation checkpoint inhibitors are designed to address resistance mechanisms, while biomarker discovery is enabling clinicians to identify patients more likely to respond. In cell therapy, improvements in T-cell engineering, gene editing, vector design, and manufacturing are supporting more consistent therapeutic products.

The FDA has continued expanding approvals for cellular and gene therapies, reflecting increasing regulatory experience with these technologies. Advances are broadening treatment options across hematologic and solid cancers, while encouraging pharmaceutical companies to invest in differentiated platforms, combination regimens, and personalized approaches that can improve clinical outcomes.

The integration of artificial intelligence, genomic profiling, and advanced diagnostics is accelerating immuno-oncology development. Molecular characterization can reveal tumor-specific targets and immune signatures, helping researchers design therapies with greater specificity. Improvements in automated manufacturing and closed-system processing can reduce variability in cell-based production. Combination strategies that pair checkpoint blockade with targeted therapies, antibody-based treatments, or cellular approaches are being evaluated to overcome treatment resistance.

Restraint - Complex Manufacturing and Supply Chain Constraints for Cell Therapies

Cell therapies face complex manufacturing and supply chain requirements that can limit commercialization and access. Autologous CAR-T products require collection of a patient's cells, transportation to facilities, genetic modification, expansion, quality testing, and return shipment before administration. This process creates requirements for temperature control, chain of identity, logistics coordination, and manufacturing capacity. Variability in starting material can also affect production timelines and product quality.

Supply constraints can become particularly challenging as demand for cell therapies expands across additional indications and treatment lines. Manufacturing facilities require sophisticated equipment, specialized reagents, viral vectors, skilled technicians, and rigorous procedures. Limited availability of some inputs may increase lead times and expose producers to procurement risks. Autologous products also have limited flexibility because each treatment is manufactured for an individual patient.

Opportunity - Technological Convergence with Personalized Vaccines and Bispecifics

The convergence of immuno-oncology with personalized vaccines and bispecific therapies creates an opportunity to improve treatment specificity and overcome resistance. Personalized cancer vaccines can be designed around tumor-specific neoantigens, potentially stimulating immune responses against tumors. Advances in sequencing and computational prediction are making identification of relevant targets more practical.

Bispecific antibodies can simultaneously engage immune cells and tumor-associated targets, creating more focused mechanisms of action. Combining these approaches with checkpoint inhibition may enhance immune activation and broaden responses in patients who do not benefit from single therapy. This convergence could support differentiated treatment strategies and strengthen pipelines across multiple cancer indications.

Partnerships among pharmaceutical companies, biotechnology firms, diagnostic developers, and academia can accelerate development of these emerging platforms. Personalized vaccines require capabilities spanning tumor sequencing, bioinformatics, manufacturing, and clinical delivery, while bispecific programs demand advanced antibody engineering and safety evaluation. Companion diagnostics can improve patient selection by identifying biomarkers for treatment.

Product Type Insights

Checkpoint inhibitors are expected to lead, accounting for 45% of revenue in 2026, due to their established clinical efficacy, broad regulatory approvals, and extensive use across multiple solid and hematologic cancers. Increasing adoption of combination treatments and biomarker-guided therapies is strengthening their market position. For example, Merck’s Keytruda (pembrolizumab) has received approvals across a broad range of cancer indications.

Immune cell therapy (CAR-T) is likely to represent the fastest-growing segment, supported by expanding regulatory approvals, advances in T-cell engineering, improved manufacturing technologies, and increasing use in relapsed or refractory cancers. Ongoing development of next-generation and potentially off-the-shelf cell therapies is expected to broaden adoption. For instance, Bristol Myers Squibb’s Breyanzi has expanded into additional lymphoma indications.

Indication Insights

Malignant tumors are projected to lead the market, capturing around 98% of the revenue share in 2026, supported by the primary use of immuno-oncology therapies for treating cancer and the substantial global burden of malignant diseases. Growing adoption of checkpoint inhibitors, monoclonal antibodies, and cellular therapies across different tumor types continues to support segment leadership. Pembrolizumab is widely used in the treatment of several malignant tumors.

Malignant tumors are also likely to be the fastest-growing indication due to expanding approvals, combination treatment strategies, improved biomarker identification, and increasing application of immunotherapies in earlier treatment settings. Continued clinical research is also extending immuno-oncology into cancers with historically limited treatment options. Pembrolizumab-based combination therapies continue expanding across multiple cancer indications.

North America Immuno-Oncology Market Trends

North America is anticipated to be the leading region, accounting for a market share of 44% in 2026, supported by advanced cancer-care infrastructure, strong clinical-trial activity, high research spending, and rapid regulatory adoption of innovative therapies. The U.S. continues to drive regional growth through frequent FDA approvals, expanding checkpoint-inhibitor indications, and increasing adoption of cell therapies. For example, in June 2026, the FDA approved Orca Bio’s Tregzi, an allogeneic regulatory T-cell immunotherapy for adults with hematologic malignancies.

U.S. Immuno-Oncology Market Trends

The U.S. is expected to dominate the regional market, accounting for approximately 80% of the market share in 2026, driven by strong oncology research and rapid commercialization of novel immunotherapies. FDA approvals continue expanding treatment options across cancer types. In June 2026, the FDA approved Gilead’s Trodelvy with pembrolizumab for first-line triple-negative breast cancer. CAR-T adoption is also expanding into additional hematologic malignancies.

Canada Immuno-Oncology Market Trends

Canada is likely to be a significant market for immuno-oncology and holds approximately 20% of the market share in 2026, supported by its immuno-oncology ecosystem through oncology research, clinical trials, and improving access to innovative therapies. Provincial cancer systems remain important for treatment adoption and reimbursement. Increasing participation in international oncology trials is supporting clinical development. The country is also benefiting from advances in biomarker-based treatment selection and combination therapies. Growing demand for innovative cancer treatments is encouraging pharmaceutical companies to expand clinical programs.

Europe Immuno-Oncology Market Trends

Europe is likely to be a significant market for immuno-oncology in 2026. Europe is experiencing continued immuno-oncology expansion through centralized regulatory oversight, growing clinical research, and increasing adoption of checkpoint inhibitors, antibody therapies, and advanced treatments. The EMA continues to review new cancer medicines and indication extensions, supporting broader therapeutic access. For instance, in May 2026, the EMA recommended expanding Merck’s Keytruda with enfortumab vedotin for resectable muscle-invasive bladder cancer.

U.K. Immuno-Oncology Market Trends

The U.K. is likely to be a significant market for immuno-oncology, estimates of 15% of Europe market share in 2026, supported by the NHS, established cancer research networks, and strong academic capabilities. Immunotherapy adoption is expanding through clinical trials and evidence-based treatment pathways. The country remains an important location for multinational oncology studies. In July 2026, Greenwich LifeSciences received approval to expand its Phase III immunotherapy trial into U.K. sites.

Germany Immuno-Oncology Market Trends

Germany is anticipated to dominate the regional market, accounting for around 37% of the Europe market share in 2026, due to increasing demand for low-ABV beverages among younger urban consumers. Supermarkets and convenience stores are expanding shelf space for flavored RTD products, including watermelon hard seltzers. Sustainability is a key trend, with strong preference for recyclable aluminum cans. Regulatory clarity around flavored alcoholic beverages is also supporting new product launches.

Asia Pacific Immuno-Oncology Market Trends

The Asia Pacific region is likely to be the fastest-growing region, supported by large cancer patient population, improving healthcare infrastructure, expanding clinical-trial activity, and increasing availability of immunotherapies. Local biotechnology companies are also strengthening regional innovation and manufacturing capabilities. A notable example includes ImmuneOnco Biopharmaceuticals in China, which is developing therapies designed to activate both innate and adaptive immune responses, reflecting the region’s growing domestic immuno-oncology pipeline.

China Immuno-Oncology Market Trends

China is projected to dominate the regional market, holding around a 30% share of the market in 2026, due to its immuno-oncology capabilities through domestic drug development, clinical research, and growing biotechnology investment. Local companies are developing checkpoint inhibitors and next-generation immune therapies. Regulatory improvements are supporting faster development of innovative oncology medicines. Domestic manufacturing capabilities are also improving treatment availability.

India Immuno-Oncology Market Trends

India is expected to emerge as a significant market, accounting for approximately 22% share in 2026, due to rising cancer awareness, expanding oncology infrastructure, clinical research, and growing biopharmaceutical capabilities. Domestic companies are increasingly developing affordable cancer therapies and advanced biologics. CAR-T development is also gaining attention as local manufacturing capabilities improve. Growing laboratory and biopharmaceutical infrastructure is supporting research activity.

The global immuno-oncology market exhibits a moderately fragmented structure, driven by strong innovation in checkpoint inhibitors, CAR-T therapies, monoclonal antibodies, and combination treatments. With key leaders including Merck & Co., Bristol Myers Squibb, F. Hoffmann-La Roche, Novartis, AstraZeneca, GSK, Pfizer, Sanofi, and AbbVie, competition remains centered on expanding indications, strengthening clinical pipelines, and developing next-generation immune-based therapies.

These players compete through differentiated drug development, strategic partnerships, clinical trials, regulatory approvals, and expansion into earlier treatment lines and additional tumor types. Companies are increasingly combining checkpoint inhibitors with antibody-drug conjugates, targeted therapies, and other immune-modulating approaches to improve treatment responses.

Key Industry Developments:

• In August 2026, City of Hope launched the ARPA-H-funded IMMUNO-BIOMAP Phase 2 trial to develop biomarker-guided strategies for predicting immunotherapy response and optimizing treatment duration in metastatic NSCLC.